Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Cellectar Biosciences Inc CLRB

Healthcare Biotechnology
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company’s lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with... see more

Current News (NDAQ:CLRB)

Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference

GlobeNewswire 9 days ago

Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies

GlobeNewswire December 16, 2025

Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire November 13, 2025

Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025

GlobeNewswire November 6, 2025

Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma

GlobeNewswire October 27, 2025

Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research

GlobeNewswire October 14, 2025

Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million

GlobeNewswire October 7, 2025

Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM)

GlobeNewswire October 6, 2025

Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer

GlobeNewswire September 30, 2025
View More News ››

Opinion & Analysis (NDAQ:CLRB)

VIDEO: Cellectar Biosciences new technology to help treat cancer

BTV-Business Television November 5, 2014
View More Opinion ››

Bullboard Posts (NDAQ:CLRB)

Sell buddy sell.

Otherwise LOSO for shareholders today with this stock
coolfooldumbguy - October 27, 2025

CLRB....sold all into the low vol strength this a.m

No position.....will add on re-load on weakness Cheers !
Iseneschal - July 22, 2025

CLRB.....I have a possible breakout on this

Big Fat Blue Breakout line at $5.47....it's getting close ; ) Currently at $5.26
Iseneschal - July 21, 2025

CLRB......I'm the 1st to post on this since 2020 !!!!

Just started a position  Cheers & Happy Fryday !
Iseneschal - July 18, 2025

CLRB up in PM with Volume

Cellectar Biosciences (CLRB) Using its patented phospholipid drug conjugates (PDCs) delivery platform to specifically target cancer...
mattusvi - July 30, 2020

FDA Import Alert

For the record, the FDA Import Alert stopping CLR131 imports from CPDC can be found at  https://www.accessdata.fda.gov/cms_ia...
aee - January 21, 2019
View more Bullboard ››

BioVaxys Technology Corp.

BioVaxys Technology Corp.

BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms ...
View More »

Podcasts